Polycyclic compounds for use in treating ocular neurodegenerative diseases

Abstract

Described herein are various compounds for treatment of ocular neurodegenerative diseases, including but not limited to glaucoma and diabetic retinopathy. The compounds described herein can act to attenuate and/or block calcium release from external neuronal environments as well as intracellular stores.

1 . An azatricyclo[6.3.0.0 2,6 ] undecane compound suitable for treating an ocular neurodegenerative disease of the following general formula: 
     
       
         
         
             
             
         
       
     
     wherein R includes one of an alkyl group that has one to twelve carbon atoms or a phenyl group. 
   
   
       2 . The compound of  claim 1 , wherein R includes the alkyl group. 
   
   
       3 . The compound of  claim 2 , the alkyl group is a linear alkyl group. 
   
   
       4 . The compound of  claim 2 , wherein the alkyl group is a branched alkyl group. 
   
   
       5 . The compound of  claim 1 , wherein R includes the phenyl group. 
   
   
       6 . The compound of  claim 5 , wherein the phenyl group includes a linear, cyclic, or branched alkyl group. 
   
   
       7 . The compound of  claim 6 , wherein the linear, cyclic, or branched alkyl group includes one to twelve carbon atoms. 
   
   
       8 . The compound of  claim 6 , wherein the linear, cyclic, or branched alkyl group includes a hydroxyl substituent. 
   
   
       9 . The compound of  claim 6 , wherein the linear, cyclic, or branched alkyl group includes a halogen substituent. 
   
   
       10 . The compound of  claim 1 , wherein R is one of —CH 3 , —(CH 2 ) 3 —CH 3 , —(CH 2 ) 7 —CH 3 , —CH 2 —C 6 H 5 , —(CH 2 ) 2 —C 6 H 5 , —(CH 2 ) 3 —C 6 H 5 , —CH 2 CH 3 , —(CH 2 ) 11 —CH 3 , —CH 2 CH(CH 3 ) 3 , —(CH 2 ) 5 —CH 3 , —C(CH 3 ) 2 —CH 2 —C(CH 3 ) 3 , —(CH 2 ) 9 —CH 3 , —CH 2 —CH 2 —OH, or —C 6 H 5 . 
   
   
       11 . The compound of  claim 1 , wherein one of A or B is hydrogen. 
   
   
       12 . The compound of  claim 11 , wherein the other of A or B is a methyl group. 
   
   
       13 . The compound of  claim 1 , wherein A and B are hydrogen. 
   
   
       14 . The compound of  claim 1 , wherein the ocular neurodegenerative disease is one of glaucoma or diabetic retinopathy. 
   
   
       15 . The compound of  claim 1  being N-phenylpropyl-3,11-azatricyclo[6.3.0.0 2,6 ] undecane. 
   
   
       16 . The compound of  claim 1  being N-(pyridin-4-ylmethyl)-3,11-azatricyclo[6.3.0.0 2,6 ] undecane. 
   
   
       17 . The compound of  claim 1  being N-(3-methoxybenzyl)-3,11-azatricyclo[6.3.0.0 2,6 ] undecane. 
   
   
       18 . The compound of  claim 1  being N-cyclohexylmethyl-3,11-azatricyclo [6.3.0.0 2,6 ] undecane. 
   
   
       19 . The compound of  claim 1  being N-benzyl-3,11-azatricyclo [6.3.0.0 2,6 ]undecane. 
   
   
       20 . A pharmaceutical composition comprising, as an active ingredient, the compound of  claim 1  in combination with a diluent to create an aqueous solution that is configured for topical administration for treatment of an ocular neurodegenerative disease.